SCM
RLMD icon

Sio Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Sio Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-235,600
Closed -$822K – 54
2022
Q4 		$822K Sell
235,600
-370,600
-61% -$3.25M 0.3% 34
2022
Q3 		$22.4M Buy
+606,200
New +$16.8M 7.13% 5

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sio Capital Management's RLMD Position: Q1 2026 in Review

Sio Capital Management opened a new position in Relmada Therapeutics (RLMD) in Q1 2026: 965,000 shares worth $6.72M. The stake represents 0.96% of the portfolio and ranks #34 among its holdings. This is a return to the name: Sio Capital Management previously reported a position in RLMD as recently as Q4 2022.

Sio Capital Management first reported a position in RLMD in Q4 2022 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Sio Capital Management held 965,000 shares of Relmada Therapeutics worth $6.72M as of Q1 2026.
  • Relmada Therapeutics was a new Sio Capital Management position in Q1 2026.
  • Relmada Therapeutics made up 0.96% of Sio Capital Management's portfolio in Q1 2026, its #34 holding.
  • Sio Capital Management first reported a position in Relmada Therapeutics in Q4 2022 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Sio Capital Management's 13F filing for Q1 2026, filed 14 May 2026.